MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and Orion Corporation announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production.
Pages
- Contact us
- Copyright
- Forward-looking statement
- General PO terms and conditions
- MSD | Home
- Our commitment to accessibility for all
- Purchase order terms and conditions
- Responsible Vulnerability Disclosure Program of MSD
- Sitemap
- Stories
- Supplemental Product Information
- Terms of use
- What we do
- Who we are
- History
- Sustainability
- Environmental sustainability
- Impact investing
- MSD Medical Outreach Program
- Philanthropy
- A closer look: MSD Richard T. Clark Fellowship for Global Health
- Advancing equity in cancer care
- Advancing patient-centered cancer care
- Advancing patient-centered cancer care in resource-limited communities
- Enhancing diabetes care through community outreach and support
- Expanding access to cancer care in Asia
- Global emergency response
- Improving access to high-quality diabetes care
- Improving access to HIV care in sub-Saharan Africa
- Improving health care access
- MSD Foundation
- MSD Richard T. Clark Fellowship for Global Health
- Product donation programs
- Promoting equity in HIV/AIDS care
- Strengthening our communities
- Sustainability resources
- Transparency disclosures
- Leadership
- Culture & values
- Diversity & inclusion
- Policies & positions
- Business development & licensing
- Suppliers
- Research
- Business development and licensing
- COVID-19
- Immunology
- Meet our scientists
- Neuroscience
- Publications
- R&D locations
- Safety Data Sheets
- Scientific capabilities
- Vaccines
- Infectious diseases
- Oncology
- Cardio-metabolic diseases
- Pipeline
- Discovery & development
- Clinical Trials
- Diversity in clinical trials
- Product patents
- Product patents
- Patients
- Media
Archives
Categories
- No categories